Sugi Predict
/ Targets
/ CDK17
Top predicted compounds (top 20 by supporting neighbours, then confidence)
Clinical trials — most relevant to CDK17 by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt |
PHASE4 | COMPLETED |
| A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714) |
PHASE3 | COMPLETED |
| Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression |
PHASE2 | COMPLETED |
| Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6 |
PHASE2 | RECRUITING |
| TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer |
PHASE2 | UNKNOWN |
| Abemaciclib With or Without Atezolizumab for mCRPC |
PHASE2 | COMPLETED |
| Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors |
PHASE1/PHASE2 | COMPLETED |
| Bryostatin 1 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer |
PHASE2 | COMPLETED |
| A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors |
PHASE1/PHASE2 | COMPLETED |
| CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Histology-Independent Study of Palbociclib in Patients With Advanced Cancer |
PHASE2 | WITHDRAWN |
| Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer |
PHASE2 | RECRUITING |
| Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC |
PHASE2 | ACTIVE_NOT_RECRUITING |
| MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer. |
PHASE2 | COMPLETED |
| A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation |
PHASE2 | ACTIVE_NOT_RECRUITING |
| RESOLVE: Abemaciclib + Letrozole +/- Metformin or Gedatolisib in Endometrial Cancer |
PHASE2 | RECRUITING |
| AZD1775 for Advanced Solid Tumors |
PHASE1 | COMPLETED |
| A Clinical Study of TQB3824 in Subjects With Advanced Cancer |
PHASE1 | UNKNOWN |
| Open Label Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms |
PHASE1 | COMPLETED |
| Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas |
PHASE1 | COMPLETED |
| Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1) |
PHASE1 | COMPLETED |
| Study of PHA-848125AC in Adult Patients With Advanced/Metastatic Solid Tumors |
PHASE1 | COMPLETED |
| A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers |
PHASE1 | COMPLETED |
| Combination Chemotherapy in Treating Patients With Refractory or Recurrent Solid Tumors |
PHASE1 | COMPLETED |
| Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic Cancer |
PHASE1 | NOT_YET_RECRUITING |
| Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma |
PHASE1 | COMPLETED |
| Advanced Breast Cancer Study of CDK4/6 Inhibitor Combined With Endocrine Therapy Endocrine Therapy in HR+/HER2- Advanced Breast Cancer |
nan | UNKNOWN |
| Incidence of Venous Thromboembolism and Cardiovascular Events in Breast Cancer Patients Undergoing Cyclin-dependent Kinase 4/6 Inhibitors: The Breast Cancer Associated Vascular Events During Cyclin-dependent Kinase 4/6 Inhibitors Therapy (BRAVE-Cyclin) Study |
nan | ACTIVE_NOT_RECRUITING |
| Study Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up Period |
nan | UNKNOWN |
| Outcome of Tucidinostat-Based Therapy in HR+ Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitor |
nan | UNKNOWN |
Related proteins — ESM-2 sequence neighbours (a CDK17 binder may also engage these)